mercaptopurine and Neurofibromatosis-1

mercaptopurine has been researched along with Neurofibromatosis-1* in 1 studies

Other Studies

1 other study(ies) available for mercaptopurine and Neurofibromatosis-1

Article	Year
[Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2003, Volume: 10, Issue:10 The triple association of leukemia, xanthogranulomas, and type 1 neurofibromatosis was first described in 1958. Most leukemias were juvenile myelomonocytic leukemias (JMML), usually called juvenile chronic myelogenous leukemia. We describe a 22-month-old female child with neurofibromatosis 1, xanthomagranulomas, and a JMML. Her mother and her brother also had cutaneous café-au-lait spots. Our patient was treated with mercaptopurine and improved. However, 9 months later she experienced a blastic transformation. The presence of xanthomagranulomas and NF1 in a young child should alert to a possible development of JMML, especially in patients with a family history of NF1. Topics: Antimetabolites, Antineoplastic; Comorbidity; Female; Humans; Infant; Leukemia, Myelomonocytic, Chronic; Mercaptopurine; Neurofibromatosis 1; Xanthogranuloma, Juvenile	2003

Article

Year

[Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2003, Volume: 10, Issue:10

The triple association of leukemia, xanthogranulomas, and type 1 neurofibromatosis was first described in 1958. Most leukemias were juvenile myelomonocytic leukemias (JMML), usually called juvenile chronic myelogenous leukemia. We describe a 22-month-old female child with neurofibromatosis 1, xanthomagranulomas, and a JMML. Her mother and her brother also had cutaneous café-au-lait spots. Our patient was treated with mercaptopurine and improved. However, 9 months later she experienced a blastic transformation. The presence of xanthomagranulomas and NF1 in a young child should alert to a possible development of JMML, especially in patients with a family history of NF1.

Topics: Antimetabolites, Antineoplastic; Comorbidity; Female; Humans; Infant; Leukemia, Myelomonocytic, Chronic; Mercaptopurine; Neurofibromatosis 1; Xanthogranuloma, Juvenile

2003